Biomednewsbreaks - Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports First Half 2026 Results, Advances Gelrinc(R) Pivotal Trial

(MENAFN- Investor Brand Network) Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, reported financial results for the six months ended June 30, 2026 and provided a corporate and clinical update. The company has recruited and treated 43 of 80 patients in its pivotal Phase III GelrinC(R) U.S. trial and now expects to complete enrollment around year-end. Regentis also expanded its U.S. and European clinical networks, advanced preparations for European commercialization and received regulatory approval in Europe for a new solvent-free manufacturing process that increases GelrinC(R) production yield by 400%. For the first half, Regentis reported a net loss of approximately $2.6 million, or $0.44 per share, compared with approximately $3.2 million, or $1.17 per share, a year earlier. The company completed a $6.5 million private placement in June and ended the period with approximately $9 million in cash and cash equivalents and no debt.

To view the full press release, visit

About Regentis Biomaterials

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis' lead product GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

“This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement.”

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company's newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

MENAFN11092026000224011066ID1111653034